Pulmonx Corp

For the period ended Dec 31, 2025. Filed Mar 10, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 10, 2026

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at December 31, 2023	38,516,383	$39	$526,797	$2,640	$(411,161)	$118,315
Issuance of common stock upon vesting of restricted stock units	987,828	1	(1)	—	—	—
Issuance of common stock upon exercise of stock options	107,817	—	218	—	—	218
Issuance of shares pursuant to employee stock purchase plan	173,941	—	1,240	—	—	1,240
Stock-based compensation expense	—	—	22,957	—	—	22,957
Currency translation adjustment	—	—	—	(466)	—	(466)
Change in unrealized losses on marketable securities	—	—	—	(61)	—	(61)
Net loss	—	—	—	—	(56,394)	(56,394)
Balances at December 31, 2024	39,785,969	40	551,211	2,113	(467,555)	85,809
Issuance of common stock upon vesting of restricted stock units	1,492,336	2	(2)	—	—	—
Issuance of common stock upon exercise of stock options	145,435	—	249	—	—	249
Issuance of shares pursuant to employee stock purchase plan	249,908	—	754	—	—	754
Stock-based compensation expense	—	—	21,060	—	—	21,060
Currency translation adjustment	—	—	—	269	—	269
Change in unrealized losses on marketable securities	—	—	—	(22)	—	(22)
Net loss	—	—	—	—	(54,003)	(54,003)
Balances at December 31, 2025	41,673,648	$42	$573,272	$2,360	$(521,558)	$54,116

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.